Auris Formulations for Treating Otic Diseases and Conditions

Patent metadata

Field	Value
Publication number	US-2016095902-A1
Application number	US-201514745160-A
Country	US
Kind code	A1
Filing date	Jun 19, 2015
Priority date	Apr 21, 2008
Publication date	Apr 7, 2016
Grant date	—

Abstract

Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

First claim

1 .- 20 . (canceled)

21 . A method of treating or prevent hearing loss, the method comprising intratympanically administering an otic composition to a subject in need thereof, wherein the otic composition comprises an auris sensory cell modulator and an auris acceptable gel, wherein the auris sensory cell modulator is an otic hair cell growth factor modulator.

22 . The method of claim 21 , wherein the auris acceptable gel has a gelation viscosity between about 100 cP and about 1,000,000 cP.

23 . The method of claim 21 , wherein the auris acceptable gel is capable of being injected by a narrow gauge needle or cannula through the tympanic membrane to an area on or near the round window membrane.

24 . The method of claim 21 , wherein the otic composition has an osmolarity of from about 100 mOsm/L to about 500 mOsm/L.

25 . The method of claim 21 , wherein the auris sensory cell modulator is a multiparticulate auris sensory cell modulator.

26 . The method of claim 25 , wherein the multiparticulate auris sensory cell modulator is micronized auris sensory cell modulator.

27 . The method of claim 21 , wherein the otic composition has a pH between 7.0 and 8.0.

28 . The method of claim 21 , wherein the otic hair cell growth factor modulator modulates receptor of at least one otic hair cell growth factor.

29 . The method of claim 28 , wherein the at least one otic hair cell growth factor is selected from neurotroph is brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), glial cell-line derived neurotrophic factor (GDNF), neurotrophin-3, neurotrophin-4, fibroblast growth factor (FGF), insulin-like growth factor (IGF), epidermal growth factor (EGF), platelet-derived growth factor (PGF), or combination thereof.

30 . The method of claim 21 , wherein sustained release of the auris sensory cell modulator into the cochlea occurs for a period of at least 5 days after a single administration.

31 . A method of treating or prevent hearing loss, the method comprising intratympanically administering an otic composition to a subject in need thereof, wherein the otic composition comprises an auris sensory cell modulator and an auris acceptable gel, wherein the auris sensory cell modulator is a neurotroph.

32 . The method of claim 31 , wherein the neurotroph prevents cells from initiating apoptosis.

33 . The method of claim 31 , wherein the neurotroph repairs damaged neurons and otic hair cells.

34 . The method of claim 31 , wherein the neurotroph induces differentiation in progenitor cells.

35 . The method of claim 31 , wherein the auris acceptable gel has a gelation viscosity between about 100 cP and about 1,000,000 cP.

36 . The method of claim 31 , wherein the auris acceptable gel is capable of being injected by a narrow gauge needle or cannula through the tympanic membrane to an area on or near the round window membrane.

37 . The method of claim 31 , wherein the otic composition has an osmolarity of from about 100 mOsm/L to about 500 mOsm/L.

38 . The method of claim 31 , wherein the neurotroph is a multiparticulate neurotroph.

39 . The method of claim 31 , wherein the otic composition has a pH between 7.0 and 8.0.

40 . The method of claim 31 , wherein sustained release of the neurotroph into the cochlea occurs for a period of at least 5 days after a single administration.

Assignees

• Otonomy Inc
• Univ California

Inventors

• Lichter Jay
• Trammel Andrew M
• Piu Fabrice
• Ye Qiang
• Dellamary Luis A
• Lebel Carl
• Harris Jeffrey P
• Vollrath Benedikt
• Duron Sergio G
• Scaife Michael Christopher

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P27/16

  Otologicals · CPC title